Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

Raphael Itzykson*, Simon Crouch, Erica Travaglino, Alex Smith, Argiris Symeonidis, Eva Hellström-Lindberg, Guillermo Sanz, Jaroslav Çermák, Reinhard Stauder, Chiara Elena, Ulrich Germing, Moshe Mittelman, Saskia Langemeijer, Krzysztof Madry, Aurelia Tatic, Mette Skov Holm, Antonio Medina Almeida, Aleksandar Savic, Njetočka Gredelj Šimec, Elisa LuñoDominic Culligan, Agnes Guerci-Bresler, Luca Malcovati, Corine Van Marrewijk, David Bowen, Theo De Witte, Pierre Fenaux

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Prognosis of lower-risk (International Prognostic Scoring System [IPSS] low/intermediate-1) myelodysplastic syndrome (MDS) is heterogeneous and relies on steady-state assessment of cytopenias. We analyzed relative drops in neutrophil and platelet counts during the first 6 months of follow-up of lower-risk MDS patients. We performed a landmark analysis of overall survival (OS) of lower-risk MDS patients prospectively included in the European LeukaemiaNet MDS registry having a visit at 6 6 1 month from inclusion to assess the prognostic relevance of relative drops in neutrophils and platelets, defined as (count at landmark 2 count at inclusion)/count at inclusion. Of 2102 patients, 807 were eligible for the stringent 6-month landmark analysis. Median age was 73 years. Revised IPSS was very low, low, and intermediate/higher in 26%, 43%, and 31% of patients, respectively. A relative drop in platelets .25% at landmark predicted shorter OS (5-year OS, 21.9% vs 48.6% with platelet drop #25%, P, 1024), regardless of baseline IPSS-revised or absolute platelet counts. Relative neutrophil drop .25% had no significant impact on OS. We built a classifier based on red blood cell transfusion dependence (RBC-TD) and relative platelet drop .25% at landmark. Patients with none (62%), either (27%), or both criteria (11%) had 5-year OS of 53.3%, 32.7%, and 9.0%, respectively (P, 1024). This classifier was validated in an independent cohort of 335 patients. Combining relative platelet drop .25% and RBC-TD at 6 months from diagnosis provides an inexpensive and noninvasive way to predict outcome in lower-risk MDS. This study was registered at www.clinicaltrials.gov as #NCT00600860.

Original languageEnglish
Pages (from-to)2079-2089
Number of pages11
JournalBlood advances
Issue number16
StatePublished - 28 Aug 2018


FundersFunder number
Horizon 2020 Framework Programme634789


    Dive into the research topics of 'Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes'. Together they form a unique fingerprint.

    Cite this